Inputs by: Mr. Saransh Chaudhary, President, Global Critical Care, Venus Remedies Ltd, and CEO, Venus Medicine Research Centre (VMRC) The upcoming Union Budget 2024-2025 will determine how well India progresses with regard to achieving its stated objectives of becoming the 'Pharmacy to the World' and embracing
Global pharma major Lupin Limited (Lupin) today announced that its Unit-2 manufacturing facility located in Mandideep, India, has successfully completed a GMP inspection by the United States Food and Drug Administration (U.S. FDA). The inspection was conducted from August 7 to August 11, 2023 and concluded
Global pharma major Lupin Limited (Lupin) announced today the launch of its Satellite Laboratory in Vijayawada, Andhra Pradesh. The move is part of Lupin Diagnostics’ ongoing expansion aimed at enhancing access to high-quality testing services and increasing the diagnostics network across the country. The newly
Global pharma major Lupin Limited (Lupin) today announced that it has received tentative approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), Drospirenone Tablets, 4 mg, to market a generic equivalent of Slynd® Tablets, 4 mg, of Exeltis USA Inc. Drospirenone
Zydus, an innovation driven global pharma major and TLC, a specialty pharmaceutical company in Taiwan, today announced the signing of a license supply and commercialization agreement to commercialize AmphoTLC™ (Amphotericin B Liposome for Injection 50mg) in India. AmphoTLC™ is a critical drug to treat Mucormycosis
